Tirzepatide

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, approved by the FDA in 2022 as Mounjaro for type 2 diabetes and in 2023 as Zepbound for chronic weight management. It is a 39-amino acid synthetic peptide engineered to activate both the GIP receptor and the GLP-1 receptor simultaneously — a mechanism that fundamentally distinguishes it from all prior incretin-based therapies, including semaglutide, liraglutide, and dulaglutide. The development of tirzepatide represents a pivotal moment in metabolic pharmacology: the deliberate co-activation of two complementary incretin pathways to produce a degree of metabolic benefit that neither pathway could achieve independently.

The dual agonism of tirzepatide arises from its molecular architecture. Tirzepatide is a fatty-acid-conjugated peptide — like semaglutide — in which a C20 fatty diacid moiety is attached via a linker to allow albumin binding. This albumin binding is the pharmacokinetic key that extends tirzepatide's half-life to approximately 5 days, enabling once-weekly subcutaneous dosing without requiring depot formulations or additional chemical modifications such as the DAC (Drug Affinity Complex) modification used in CJC-1295. The core peptide sequence is optimised to activate GLP-1 receptors and GIP receptors with near-equal affinity at both target sites, a so-called "balanced" agonist design intended to capture the full complementary biology of both incretins without over-weighting either.

To understand why dual agonism matters, it is essential to understand the distinct but complementary roles of GLP-1 and GIP in normal metabolic physiology. GLP-1 (glucagon-like peptide-1) is released primarily from L-cells in the distal small intestine and colon in response to nutrient ingestion. It acts on GLP-1 receptors in the pancreas to stimulate glucose-dependent insulin secretion, on alpha cells to suppress glucagon release, on the stomach to delay gastric emptying, and on the hypothalamus and brainstem to activate satiety signalling and reduce appetite. These are the same mechanisms that pure GLP-1 agonists such as semaglutide exploit. GIP (glucose-dependent insulinotropic polypeptide) is released from K-cells in the proximal small intestine — primarily the duodenum — earlier in the meal than GLP-1 and has overlapping but distinct effects. GIP stimulates insulin secretion synergistically with GLP-1, promotes adipocyte lipolysis via GIPR activation, has anabolic effects on bone, and — importantly — appears to attenuate the nausea that GLP-1 receptor activation tends to produce via central vagal mechanisms. This last effect may explain a consistent observation in comparative trials: tirzepatide's GI tolerability profile, particularly nausea, is generally superior to pure GLP-1 agonists despite producing greater weight loss.

The SURMOUNT-1 clinical trial, the pivotal registration trial for tirzepatide in obesity (without diabetes), produced results that fundamentally altered expectations in metabolic medicine. Published in the New England Journal of Medicine in 2022, the trial enrolled 2,539 adults with obesity (BMI ≥ 30) or overweight with at least one weight-related comorbidity. At the 15 mg weekly dose, participants lost an average of 20.9% of their baseline body weight over 72 weeks. At 10 mg, weight loss was 19.5%, and at 5 mg, 15.0%. Notably, 37.0% of participants at the 15 mg dose achieved weight loss of 25% or more — a result approaching or matching average outcomes from bariatric surgery. These numbers eclipsed all prior pharmacotherapy results and established tirzepatide as the most effective anti-obesity medication ever evaluated in a Phase 3 trial.

In the SURPASS trial series for type 2 diabetes (SURPASS-1 through SURPASS-5), tirzepatide consistently outperformed semaglutide 1 mg (the approved diabetes dose) on both glycaemic control (HbA1c reduction) and body weight reduction. In SURPASS-2, the head-to-head comparison, tirzepatide at 10 and 15 mg reduced HbA1c by 2.01% and 2.30% respectively versus semaglutide's 1.86% reduction. Weight loss was 8.5 kg and 11.2 kg with tirzepatide (10 and 15 mg) versus 6.2 kg with semaglutide 1 mg. At every dose level studied, tirzepatide's dual agonism produced better outcomes than single-pathway GLP-1 agonism.

At the molecular level, tirzepatide's fat-modification design follows the same albumin-binding pharmacokinetic principle pioneered with semaglutide but with a different fatty acid and linker structure that accommodates activation of both GIP and GLP-1 receptors without compromising either. The half-life of approximately 5 days (slightly shorter than semaglutide's 7-day half-life) is sufficient for weekly dosing and allows meaningful dose-to-dose accumulation over the 4–20 week titration period.

Research interest in tirzepatide extends well beyond its currently approved metabolic indications. Trials are underway in non-alcoholic steatohepatitis (NASH/MASH), where GLP-1 receptor activation has documented hepatoprotective effects and GIP receptor activation may add additional benefit via adipose-liver crosstalk. Studies in heart failure with preserved ejection fraction (HFpEF) — where obesity is a central driver — and obstructive sleep apnoea are also ongoing. SUMMIT trials in HFpEF have shown meaningful benefits in exercise tolerance and symptoms, adding to a growing body of evidence that incretin-based therapies have systemic benefits beyond glycaemic and weight control.

For researchers comparing tirzepatide to semaglutide, the key practical distinctions are: tirzepatide produces approximately 3–5% greater absolute weight loss at maximum doses; its GI tolerability may be modestly better due to GIP-mediated nausea attenuation; it is available only as a subcutaneous injection (no oral formulation exists, unlike oral semaglutide 14 mg which was approved for diabetes); its dosing range is 2.5 to 15 mg weekly with mandatory slow titration; and its mechanism of dual receptor activation provides unique research value for understanding GIP biology and incretin co-agonism. In the research peptide space, tirzepatide has become the benchmark against which next-generation metabolic peptides — including the triple agonist retatrutide — are measured.